Related Experiment Video
Updated: May 11, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Outcomes of correcting hyponatremia in patients with myocardial infarction
Waqas Qureshi1, Syed Hassan, Fatima Khalid
1Department of Internal Medicine, Henry Ford Health Systems/Wayne State University School of Medicine, 2799 W Grand Blvd, CFP-1, Detroit, MI 48202, USA.
Insights
Hyponatremia in myocardial infarction patients predicts mortality, whether corrected or persistent. However, correcting hyponatremia may improve survival, especially with vaptan use.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Hyponatremia is a known predictor of poor outcomes in heart failure.
- Its prognostic significance in myocardial infarction (MI) and the impact of correction remain unclear.
Purpose of the Study:
- To assess the prognostic value of hyponatremia in MI patients.
- To determine if correcting hyponatremia affects all-cause mortality.
Main Methods:
- Retrospective analysis of 11,562 MI patients (2000-2010) with serum sodium measured within 24 hours of admission.
- Multivariate and Cox proportional hazard models used to identify predictors of all-cause mortality and adjusted survival.
Main Results:
- 1,535 deaths (13.3%) occurred over a mean follow-up of 5.5 years.
- Both corrected (27.9% deaths) and persistent (55.3% deaths) hyponatremia independently predicted mortality (p < 0.0001).
- Vaptan use was associated with reduced mortality in hyponatremic patients (HR 0.45; p=0.005).
Conclusions:
- Hyponatremia, corrected or persistent, predicts mortality, major adverse cardiac events, and rehospitalization in MI patients.
- Correction of hyponatremia can potentially improve patient survival.
- Vaptans show promise in reducing mortality for hyponatremic MI patients.
Background:
Hyponatremia has significant prognostic implications in patients with heart, failure. However, little data are available regarding its significance in patients presenting with myocardial infarction. In addition, it is not known if correction of hyponatremia impacts outcomes in these patients. The aim of this study was to evaluate the prognostic value of hyponatremia in patients with myocardial infarction and the effect of its correction on all-cause mortality.
Methods:
Patients with the discharge diagnosis of myocardial infarction at our institution between 2000 and 2010 with serum sodium levels measured within 24 h of admission were included in this retrospective analysis. Multivariate analysis was used to determine the predictors of all-cause mortality. Cox proportional hazard model was applied to determine the adjusted survival.
Results:
A total of 11,562 patients (67.15 ± 14.6 years, males 56.3 %) were included in the analysis. There were a total of 1,535 (13.3 %) deaths within mean follow-up duration of 5.5 ± 3.3 years. There were 425 (27.9 %) deaths in patients with corrected hyponatremia and 155 (55.3 %) deaths in persistent hyponatremia patients. Multivariate analysis indicated that corrected hyponatremia and persistent hyponatremia were independent predictors of all cause mortality (p < 0.0001). When analyzing short-term (30 days) and long-term mortality, corrected hyponatremia group did not have associated long term mortality. Various methods to correct hyponatremia were also analyzed and use of vaptans was associated with decrease in mortality in patients with hyponatremia from 115 to 125 (HR 0.45; 95 % CI 0.26-0.78, p = 0.005).
Conclusion:
Our analysis showed that corrected and persistent hyponatremia in patients presenting with myocardial infarction is a predictor of all-cause mortality, major adverse cardiac events and heart failure related 30 day rehospitalization. In certain cases, correction of hyponatremia may actually improve survival of the patients.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Mitral Regurgitation IV: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Myocarditis IV: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy VI: Nursing Management

